A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

Inclusion Criteria: * Males and females between 18 and 60 years of age * Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study * Have Relapsing Remitting Multiple Sclerosis (RRMS) according to the revised McDonald criteria 2005 * Have brain and/or spinal MRI with findings typical of Multiple Sclerosis (MS) * Have disease duration for more than 12 months * Have disease activity characterized by at least one clinical event and one or more Gadolinium-enhancing MRI lesions within the 6 months prior to randomization * Have score of \<=5.5 on the Expanded Disability Status Scale (EDSS) * Be willing and able to comply with the protocol for the duration of the study * Have given written informed consent prior to any study-related procedure not part of the normal medical practice Exclusion Criteria: * Have any disease other than MS that could better explain his/her signs and symptoms * Have complete transverse myelitis or bilateral optic neuritis * Have received or have used anytime monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy (excluding systemic steroids and adrenocorticotrophic hormone \[ACTH\]), or total lymphoid irradiation * Have received within 3 months prior to baseline any approved disease-modifying therapy for MS, cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, any investigational drug, or experimental procedure * Have received within 30 days prior to baseline oral or systemic corticosteroids or ACTH * Other protocol defined exclusion criteria could apply